Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

2.

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.

Curr Med Res Opin. 2011 Jan;27(1):79-86. doi: 10.1185/03007995.2010.536527. Epub 2010 Nov 22.

PMID:
21091127
3.

Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.

Henk HJ, Becker L, Tan H, Yu J, Kavati A, Naeim A, Deeter R, Barron R.

J Med Econ. 2013;16(1):160-8. doi: 10.3111/13696998.2012.734885. Epub 2012 Oct 11.

PMID:
23016568
4.

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.

Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G.

Clin Ther. 2009 May;31(5):1069-81. doi: 10.1016/j.clinthera.2009.05.019.

PMID:
19539108
5.

Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.

Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G.

Am J Clin Oncol. 2012 Jun;35(3):267-74. doi: 10.1097/COC.0b013e31820dc075.

PMID:
21378538
6.

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.

Liu Z, Doan QV, Malin J, Leonard R.

Appl Health Econ Health Policy. 2009;7(3):193-205. doi: 10.2165/11314740-000000000-00000.

PMID:
19799473
8.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS.

Cancer. 2009 Oct 15;115(20):4839-48. doi: 10.1002/cncr.24535.

9.

Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.

Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.

J Natl Cancer Inst. 2013 Aug 7;105(15):1078-85. doi: 10.1093/jnci/djt182. Epub 2013 Jul 19.

PMID:
23873405
10.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Lyman G, Lalla A, Barron R, Dubois RW.

Curr Med Res Opin. 2009 Feb;25(2):401-11. doi: 10.1185/03007990802636817 .

PMID:
19192985
11.

A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.

Tomic K, Long S, Li X, Fu AC, Yu TC, Barron R.

J Oncol Pharm Pract. 2013 Dec;19(4):328-37. doi: 10.1177/1078155212473001. Epub 2013 Jan 24.

PMID:
23353712
12.

Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.

Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS.

J Manag Care Pharm. 2003 Mar-Apr;9(2 Suppl):15-21.

13.

[Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].

Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.

Dtsch Med Wochenschr. 2010 Mar;135(9):385-9. doi: 10.1055/s-0030-1249174. Epub 2010 Feb 23. German.

PMID:
20180162
14.

Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.

Numnum TM, Kimball KJ, Rocconi RP, Kilgore LC, Straughn JM Jr.

Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1019-24. Epub 2007 Mar 26.

PMID:
17386043
15.

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.

Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

PMID:
24166522
16.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.

J Oncol Pharm Pract. 2016 Oct;22(5):702-16. doi: 10.1177/1078155215625459. Epub 2016 Jan 13. Review.

PMID:
26769697
17.

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH.

Value Health. 2008 Mar-Apr;11(2):172-9. doi: 10.1111/j.1524-4733.2007.00242.x.

18.

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG.

Ann Pharmacother. 2006 Mar;40(3):402-7. Epub 2006 Feb 21.

PMID:
16492793
19.

Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.

Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.

Clin Ther. 2009;31 Pt 2:2388-95. doi: 10.1016/j.clinthera.2009.11.013.

PMID:
20110048
20.

Supplemental Content

Support Center